Stimulating the Auricular Branch of the Vagus Nerve

aVNS

Nexeon MedSystems has developed a non-invasive auricular vagus nerve stimulator (aVNS) for the treatment of disease related to neurologic, inflammatory, and metabolic syndrome. Our initial clinical and commercial efforts are in atrial fibrillation (non-valvular paroxysmal) and opioid withdrawal.

Our aVNS device is a non-invasive, battery-powered, self-administered device designed to transcutaneously stimulate the auricular branch of the vagus nerve (ABVN).

The device is worn similar to headphones and is composed of a handheld generator and earpiece. The handheld control unit produces precise, current-controlled stimulation output. Electrical current is delivered through an earpiece with disposable hydrogel electrode contacts to maximize therapeutic potential and minimize the risk of patient discomfort.

Nexeon is pursuing multiple indications for the aVNS technology. Clinical activities are in progress using this technology to treat Atrial Fibrillation and Opioid Withdrawal.

Indication Milestone
Opioid withdrawal pilot Complete 2018
Opioid withdrawal pivotal Complete 2019
Opioid FDA approval 2020
Atrial fibrillation pilot Funded, complete in early 2019
Atrial fibrillation pivotal Funded, complete in early 2020
Atrial fibrillation CE Mark 2020